Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MNKD vs MESO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MNKD Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

MNKD Overall Winner 6-Pillar Tally: MNKD 4 – 2 MESO Matrix Metrics: MNKD 8 – 2 MESO

As of Nov 16, 2026, Mannkind Corporation (MNKD) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). MNKD carries a Unified Composite Score of 38.4/100 (SELL) at $3.91 (26.2x Forward P/E, -3.4% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin).

  • Growth vs. Quality Trade-Off: MNKD earns the overall head-to-head edge with a stronger Unified Composite Score (38.4/100 SELL vs. MESO 35.5/100 SELL) and 1.29β · 48% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although MNKD compares more favorably head-to-head, both MNKD (38.4/100 SELL) and MESO (35.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: MNKD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 56.7); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MNKD vs MESO
MNKD NASDAQ Head-to-Head Winner
Mannkind Corporation
Pharmaceutical Preparations
$3.91
-5.33% 1D
Market Cap $1.3B
TTM Revenue $413M
Forward P/E 26.2x
Beta / 30D Vol 1.29β · 48% Vol
Unified Composite Score
38.4 / 100 SELL
Tech 8.0 Fund 38.0 Flow 72.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 56.7 · SMA20: $3.66 · SMA50: $3.57
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
35.5 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $13.64 · SMA50: $14.22

6-Pillar Scorecard Institutional Category Breakdown (MNKD 4 – 2 MESO)

Columns: Metric · MNKD · MESO
1. Valuation Multiples MNKD
Forward P/E 26.2x N/M
Trailing P/E 32.3x N/M
PEG Ratio 4.39x N/M
EV / Revenue 3.9x 14.1x
2. Growth & Scale MESO
Revenue Growth (YoY) +24.0% +390.7%
Earnings Growth (YoY) -34.9% +0.0%
TTM Revenue (USD) $413M $120M
Market Cap $1.3B $1.7B
3. Profitability & Quality MNKD
Gross Margin 75.8% 80.0%
Operating Margin -3.4% -42.6%
Net Profit Margin -18.1% -47.8%
Return on Equity (ROE) 0.0% -9.9%
4. Balance Sheet & Cash Flow MESO
Cash Generation (TTM) -$78M -$45M EBITDA
Cash Flow Margin -19.0% -37.1% EBITDA Mgn
Net Cash / Leverage $289M Net Debt $4.38 Book/Sh · -9.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MNKD
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 66.9% (7th %ile) 76.8% (37th %ile)
Put/Call OI Skew 0.05x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat MNKD
OpEx & R&D Intensity 79.2% of Rev ($327M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MNKD (8) vs MESO (2)
Institutional Metric MNKD MESO Criterion Row Edge
Market Capitalization
Scale
$1.3B $1.7B Larger Scale MESO
Trailing P/E Ratio
Valuation
32.3x N/M Lower Multiple MNKD
Forward P/E Ratio
Valuation
26.2x N/M Lower Multiple MNKD
Revenue Growth (YoY)
Growth
+24.0% +390.7% Higher Growth MESO
Operating Margin (TTM)
Profitability
-3.4% -42.6% Higher Margin MNKD
Net Profit Margin
Profitability
-18.1% -47.8% Higher Margin MNKD
Return on Equity (ROE)
Capital Efficiency
0.0% -9.9% Higher ROE MNKD
52-Week Range Position
Momentum
39% ($2–$7) 6% ($12–$22) Stronger Trend MNKD
Beta / 30D Volatility
Risk Regime
1.29β · 48% Vol 1.18β · 78% Vol Lower Realized Risk MNKD
Unified Institutional Score
Composite Signal
38.4 / 100 (SELL) 35.5 / 100 (SELL) Higher Composite MNKD
Trailing 12M Revenue (USD)
Operating Scale
$413M $120M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.8% 80.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
4.39x PEG · 3.9x EV/Rev N/M PEG · 14.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$78M ($289M Net Debt) -$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MNKD +34.72 pp
MNKD: +28.62% · MESO: -6.1%
3M Horizon MNKD +21.26 pp
MNKD: -3.93% · MESO: -25.19%
6M Horizon MNKD +45.59 pp
MNKD: +30.77% · MESO: -14.82%
1Y Horizon MESO +6.46 pp
MNKD: -22.88% · MESO: -16.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MNKD vs MESO. Trailing 12-month operating profitability (MNKD -3.4% vs MESO -42.6%) and valuation multiples (MNKD 26.2x vs MESO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MNKD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$413M
Gross Margin75.8%
Op. Margin-3.4%
ROE / Fwd P/E0.0% · 26.2x
MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MNKD CONSOLIDATION
95d in phase · OBV ACCUMULATION
Current IV 66.9%
IV Percentile 7th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact MNKD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MNKD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -3.4% operating margin.
OpEx & R&D Reinvestment 79.2% of Rev ($327M)
90D Engineering Disclosures 0 Published
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MNKD vs MESO Key Questions & Quantitative Answers

As of Nov 16, 2026, Mannkind Corporation (MNKD) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). MNKD carries a Unified Composite Score of 38.4/100 (SELL) at $3.91 (26.2x Forward P/E, -3.4% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin). Growth vs. Quality Trade-Off: MNKD earns the overall head-to-head edge with a stronger Unified Composite Score (38.4/100 SELL vs. MESO 35.5/100 SELL) and 1.29β · 48% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although MNKD compares more favorably head-to-head, both MNKD (38.4/100 SELL) and MESO (35.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MNKD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 56.7); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MESO leads the Growth & Scale pillar: MNKD posts +24.0% YoY revenue growth and -34.9% YoY earnings growth on $413M TTM revenue (75.8% gross margin, -3.4% operating margin), compared with MESO at +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin). On trailing 12-month operating scale, MNKD generates $413M in USD-normalized revenue versus $120M for MESO. In operating R&D and SG&A reinvestment, MNKD deploys 79.2% of Rev ($327M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MESO.

MNKD screens cheaper on headline valuation multiples. MNKD trades at 26.2x Forward P/E, 32.3x Trailing P/E, 4.39x PEG, and 3.9x EV/Revenue (-19.0% FCF margin), whereas MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MNKD (0.0% ROE) versus MESO (-9.9% ROE) capital efficiency.

In options market volatility and institutional positioning, MNKD carries 66.9% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.29β · 48% Vol realized risk). By comparison, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.